Skip to search formSkip to main contentSkip to account menu

AT 13387

Known as: AT-13387, AT13387 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Hsp90 Inhibitor AT13387

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Phase I trial of the combination of the heat shock protein-90 inhibitor onalespib (AT13387) and the cyclin-dependent kinase inhibitor AT7519M in patients with advanced solid tumors.
2619 Background: The 90kDa heat shock protein (HSP90) participates in the folding, stabilization, activation, and proteolytic… 
2018
2018
The in silico identification of potent anti-cancer agents by targeting the ATP binding site of the N-domain of HSP90
ABSTRACT To identify new HSP90 inhibitors, the ATP binding site of the N-domain of HSP90 was targeted by molecular docking of a… 
2018
2018
Small Molecules Identified from a Quantitative Drug Combinational Screen Resensitize Cisplatin's Response in Drug-Resistant Ovarian Cancer Cells
2017
2017
Phase Ib study of heat shock protein 90 inhibitor, onalespib in combination with paclitaxel in patients with advanced, triple-negative breast cancer (NCT02474173).
TPS1127Background: Heat shock protein 90 (HSP90) is a molecular chaperone which is necessary for proper folding and stabilization… 
2016
2016
The investigation of AT7519 (CDK inhibitor) and AT13387 (HSP90 inhibitor) as novel therapies for the treatment of pancreatic ductal adenocarcinoma
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is usually a systemic disease and so requires chemotherapy even when surgical… 
2015
2015
Towards Personalized Cancer Therapy : New Diagnostic Biomarkers and Radiosensitization Strategies
This thesis focuses on the evaluation of biomarkers for radio-immunodiagnostics and radio-immunotherapy and on radiosensitization… 
2013
2013
Abstract 2433:In vitroandin vivoantitumor activity of the next generation HSP90 inhibitor, AT13387, in both hormone-sensitive and castration-resistant prostate cancer models.
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC HSP90 is a molecular chaperone involved in the… 
2012
2012
First-in-human phase I study: Results of a second-generation non-ansamycin heat shock protein 90 (HSP90) inhibitor AT13387 in refractory solid tumors.
3028 Background: AT13387 is a second-generation potent, novel non-ansamycin HSP90 inhibitor (IC50 0.71 nM). AT13387 has good… 
2012
2012
Abstract 2772: AT13387, an HSP90 inhibitor, is effective in both vemurafenib-sensitive and -resistant melanoma models
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Background: Mutations in BRAF are found in… 
2012
2012
Abstract 2770: Antitumor activity of heat shock protein 90 (HSP90) inhibitor AT13387 in head and neck squamous cell carcinoma
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Heat shock protein 90 (HSP90) has been shown to be… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)